Claims:

1. Liquid pharmaceutical formulation comprising anti-FXIa antibody BAY1213790 which consists of SEQ ID NO: 1 for the amino acid sequence for the heavy chain and SEQ ID NO: 2 for the amino acid sequence for the light chain at a concentration of 10 – 40 mg/ml, 10 mM histidine and 130mM glycine, wherein the formulation has a pH of 6.

2. Liquid pharmaceutical formulation according to Claim 1 comprising further ingredients selected from the group consisting of preservatives, carriers, wetting agents and stabilizers.

3. Liquid pharmaceutical formulation according to any of the preceding claims comprising 1-10% (w/v) of a stabilizer.

4. Liquid pharmaceutical formulation according to any of the preceding claims comprising 3-7% (w/v) trehalose dihydrate.

5. Liquid pharmaceutical formulation according to any of the preceding claims comprising wetting agents at a concentration of 0.001% to 0.5% (w/v).

6. Liquid pharmaceutical formulation according to Claim 5, wherein the wetting agent is polysorbate 80.

7. Liquid pharmaceutical formulation according to claim 1 comprising anti-FXIa antibody BAY1213790 at a concentration of 25 mg/ml, and further comprising 5% (w/v) trehalose dihydrate and 0.05% (w/v) polysorbate 80.

8. Lyophilizate obtainable by freeze-drying a liquid pharmaceutical formulation according to any of the preceding claims.

9. Lyophilizate according to Claim 8 comprising at most 2% residual water.

10. Dosage form comprising a liquid pharmaceutical formulation or a lyophilizate according to any of the preceding claims.

11. Dosage form according to Claim 10, wherein the dosage form is a syringe or an autoinjector.

12. Liquid pharmaceutical formulation according to any of claims 1-7 for use in the treatment or prophylaxis of thrombotic or thromboembolic disorders.